Septerna (NASDAQ:SEPN) Price Target Lowered to $11.00 at Wells Fargo & Company

Septerna (NASDAQ:SEPN) had its price objective lowered by Wells Fargo & Company from $14.00 to $11.00 in a research note published on Friday morning,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the stock.

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $50.00 price target on shares of Septerna in a report on Tuesday, February 11th.

Septerna Trading Down 3.0 %

SEPN stock opened at $6.10 on Friday. The stock has a fifty day moving average of $9.96. Septerna has a one year low of $4.17 and a one year high of $28.99.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.05. The company had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.13 million. On average, equities research analysts predict that Septerna will post -7.11 EPS for the current year.

Insiders Place Their Bets

In other Septerna news, CFO Gil M. Labrucherie purchased 5,000 shares of the stock in a transaction that occurred on Friday, February 21st. The stock was purchased at an average price of $5.85 per share, with a total value of $29,250.00. Following the acquisition, the chief financial officer now owns 30,000 shares in the company, valued at approximately $175,500. The trade was a 20.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Alan Ezekowitz acquired 41,355 shares of Septerna stock in a transaction on Thursday, March 6th. The shares were bought at an average cost of $6.00 per share, for a total transaction of $248,130.00. Following the completion of the purchase, the director now directly owns 104,101 shares of the company’s stock, valued at $624,606. The trade was a 65.91 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 74,346 shares of company stock valued at $439,670 in the last three months.

Institutional Trading of Septerna

Hedge funds and other institutional investors have recently bought and sold shares of the stock. M&T Bank Corp purchased a new position in Septerna during the fourth quarter worth $376,000. Charles Schwab Investment Management Inc. purchased a new position in shares of Septerna during the 4th quarter worth about $3,197,000. PNC Financial Services Group Inc. bought a new position in Septerna during the 4th quarter valued at about $61,000. Rhumbline Advisers bought a new position in Septerna during the 4th quarter valued at about $458,000. Finally, Lindbrook Capital LLC purchased a new stake in Septerna in the 4th quarter worth about $481,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.